Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, Poolbeg or the Company ), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need and with a lack of treatment alternatives, announces key insights from its poster presentation at the prestigious, 65th
The poster, which details POLB 001 as a potential therapy for Cytokine Release Syndrome ( CRS ) associated with cancer immunotherapies, was presented by Dr
CRS is a well-recognised toxicity that occurs frequently following certain cancer treatments such as T-cell engaging antibodies and CAR T cell therapies. In addition to patient mortality and morbidity risk, the high frequency of CRS associated with these treatments represents a barrier to outpatient delivery. The need for in-patient management of CRS adds to the overall healthcare costs of delivering these treatments and contributes to restricting their availability.
Meanwhile, the POLB 001 LPS human challenge trial conducted by Poolbeg demonstrated good safety and tolerability, a clear dose-response relationship, inhibition of p38 MAPK activation, and a reduction in all measured pro-inflammatory cytokines. The effects observed were a negation of immune over-reaction rather than an ablation of core immune function. Phase II trial enabling activities are underway with strong interest from potential pharma partners.
Contact:
Tel: +44 (0) 207 183 1499
Tel: +44 (0) 207 220 0500
About Poolbeg Pharma
Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the
Poolbeg s clinical programmes target large addressable markets including CRS induced by cancer immunotherapies, infectious disease, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further development. Its AI-led infectious disease programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal.
About ASH
The ASH Annual Meeting and Exposition is recognised as the world s premier conference focussing on haematological malignancies (blood cancers) and brings together over 25,000 industry and academic attendees each year to share the latest scientific discoveries and advances in clinical care.
(C) 2023 Electronic News Publishing, source